## Management of AA Amyloidosis **Key Point:** In secondary (AA) amyloidosis, the primary goal is to suppress the underlying inflammatory condition. TNF-α inhibitors like infliximab are the most effective agents for halting amyloid deposition by reducing serum amyloid A (SAA) production. ### Pathophysiology of AA Amyloidosis AA amyloidosis develops from chronic inflammatory states (rheumatoid arthritis, chronic infections, malignancy). The inflammatory cytokines, particularly TNF-α and IL-6, drive hepatic synthesis of serum amyloid A (SAA), the precursor protein. Reducing SAA levels is the cornerstone of treatment. ### Role of TNF-α Inhibitors 1. Infliximab (anti-TNF monoclonal antibody) suppresses TNF-α-mediated inflammation 2. Reduces SAA levels by 50–80% within weeks 3. Halts progression and may allow regression of amyloid deposits 4. Superior efficacy compared to conventional DMARDs alone in RA-associated amyloidosis **High-Yield:** TNF-α inhibitors (infliximab, etanercept, adalimumab) are first-line agents for AA amyloidosis; they address the root cause (chronic inflammation) rather than the amyloid itself. ### Why Other Agents Are Inadequate | Agent | Role in Amyloidosis | Limitation | |-------|---------------------|------------| | Colchicine | Anti-inflammatory; used in FMF | Ineffective in RA-associated AA; no SAA suppression | | Melphalan | Chemotherapy for AL amyloidosis | Not indicated for AA; toxicity without benefit | | Doxycycline | Experimental; stabilizes transthyretin | Only for hereditary ATTR; no role in AA | **Clinical Pearl:** Early aggressive TNF-α inhibition in RA can prevent amyloidosis development; once established, it may stabilize or slow progression but rarely causes complete regression. **Warning:** Colchicine is effective in familial Mediterranean fever (FMF)-associated amyloidosis but NOT in RA-associated AA amyloidosis — a common exam trap.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.